Society of Gynecologic Oncology (SGO)

A Phase 2 trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma

A phase 1/2 study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer (PROC)

Phase 2 study of durvalumab alone or in combination with ADXS11-001 (AXAL) in persistent/reccurent or metastatic cervical cancer (PRmCC)

Retrospective Observational Study of Adverse Events (AEs) in Women with Ovarian Cancer (OC) Switching from Olaparib Capsules to Tablets:US Healthcare Claims Database Study

Is toxicity burden worth the PFS benefit of second-line maintenance for epithelial ovarian cancer? Patient and provider perspectives from a discrete choice experiment

Cost-Effectiveness Analysis of Olaparib as a Maintenance Monotherapy for Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA1/2 Mutation: A United States (US) Payer Perspective

Projection of Long-Term Overall Survival among Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA1/2 Mutation

Exploring the utility and burden of clinical follow up of thresh-hold alerts generated by patient-reported outcomes in women with recurrent ovarian cancer: A longitudinal study

More toxic than treatment? The financial impact of living with ovarian cancer: A qualitative exploration of financial toxicity in women with recurrent ovarian cancer

Patient preferences for maintenance therapy vs. routine surveillance: Gain in progression-free survival and risks of adverse effects

Patient preferences for side effects and decision-making factors associated with maintenance therapy

Economic Burden Associated with the Early Progression in Ovarian Cancer

Interim results of the non-interventional C-PATROL study on the transition from olaparib capsules to tablets

Population adjusted indirect comparison of olaparib plus bevacizumab versus olaparib monotherapy, bevacizumab monotherapy and placebo in the maintenance treatment of women with newly diagnosed advanced ovarian cancer and a BRCA mutation

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial

The first study evaluating the distribution of gBRCA1/2 variants within the ovarian cancer cluster region in Japanese ovarian cancer patients

Randomized phase II CLIO study on Olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer

Population-adjusted indirect comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 studies of olaparib with or without bevacizumab, bevacizumab alone and placebo in the maintenance treatment of women with newly diagnosed stage III/IV ovarian cancer with BRCA mutation

Phase III PAOLA-1/ENGOT-ov25: maintenance olaparib with bevacizumab in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy and bevacizumab as standard of care

Maintenance olaparib plus bevacizumab after platinumbased chemotherapy with bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial